Clinical Outcome with Oral Linezolid and Rifampin Following Recurrent Methicillin‐Resistant Staphylococcus aureus Bacteremia Despite Prolonged Vancomycin Treatment
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Drug‐resistant Gram‐positive bacteria, especially Staphylococcus aureus, are emerging as the predominant organisms involved in both nosocomial and community‐acquired infections. Since the 1980s, vancomycin has been the first‐line antibiotic used to treat methicillin‐resistant S aureus. However, allergy and intolerance to vancomycin, the increasing number of vancomycin clinical failures and the existence of vancomycin intermediate‐susceptible isolates of S aureus suggest that new antibiotics are needed. This paper reports the only known case of a successful clinical outcome with long term oral linezolid and rifampin therapy in the management of recurrent and persistent methicillin‐resistant S aureus bacteremia with metastatic infections despite prolonged vancomycin use. More than two years since the initiation of linezolid and rifampin, the study patient has been clinically well with no evidence of adverse drug reactions including cytopenia and hepatic toxicities. Physicians must be aware of the novel developments in antibiotic therapy to treat drug‐resistant bacterial infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Sieradzki, K., Roberts, R. B., Haber, S. W., & Tomasz, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400704 · Cited by 638
Staphylococcus aureus resistant to vancomycin--United States, 2002.
(2002) · PubMed · Cited by 569
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K., & Quinn, J. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04376-2 · Cited by 542
STAPHYLOCOCCUS AUREUS RESISTANT TO VANCOMYCIN???UNITED STATES, 2002
&NA; (2002) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200203000-00016 · Cited by 395
Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections
Perry, C. M., & Jarvis, B. (2001) · Drugs · doi:10.2165/00003495-200161040-00008 · Cited by 275
Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996
(1997) · American Journal of Infection Control · doi:10.1016/s0196-6553(97)90087-0 · Cited by 224
Staphylococcus aureus with Reduced Susceptibility to Vancomycin
Cosgrove, S. E., Carroll, K. C., & Perl, T. M. (2004) · Clinical Infectious Diseases · doi:10.1086/422458 · Cited by 223
Research works printed but not linked: 3
- [3]3. Chang FY. Staphylococcus aureus bacteremia and endocarditis. J Microbiol Immunol Infect 2000;33:63-8.
- [12]12. Niitsuma K, Saito M. Vancomycin inhalation therapy - A pharmacokinetic and clinical study of vancomycin. Antibiot Chemother 1996;122:123-35.
- [35]35. Kaatz GW, Seo SM. In vitro activities of oxazolidinone compound U-100592 and U-100766 against S aureus and S epidermidis. Antimicrob Agents Chemother 1996;40:799-801.
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Rifampin Combination Therapy for Nonmycobacterial Infections
Forrest, G. N., & Tamura, K. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00034-09 · Cited by 242
“Lastly, there was a successful treatment of persistent MRSA bacteremia with metastatic foci by using rifampin-linezolid combination therapy (223).”
BackgroundPurrello, S., Garau, J., Giamarellos‐Bourboulis, E. J., Mazzei, T., Pea, F., Soriano, À., & Stefani, S. (2016) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2016.07.010 · Cited by 128
“Linezolid has been compared with vancomycin for SAB in several case series and observational cohorts [95–99].”
BackgroundGandelman, K., Zhu, T., Fahmi, O. A., Glue, P., Lian, K., Obach, R. S., & Damle, B. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010366445 · Cited by 108
Metadata
- Authors
- Schwalm, J.-D., El-Helou, P., & Lee, C. H.
- Affiliations
- McMaster University (CA)
- Corresponding author
- Lee, Christine H
- Venue
- Canadian Journal of Infectious Diseases and Medical Microbiology
- Publisher
- Wiley
- Published
- 2004-01
- Volume
- 15
- Issue
- 2
- Pages
- 97-100
- ISSN
- 1180-2332 (ISSN-L)
- 1712-9532
- 1918-1493
- PMC
- PMC2094963
- OpenAlex
- W2317216373
- Semantic Scholar
- 6ee4ae48afa489ebec0682c0580e50478dd39d00
- Cited by
- 16
- References
- 45
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 2 · 2021: 1 · 2020: 1 · 2018: 1 · 2016: 1 · 2015: 2 · 2013: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Canadian Journal of Infectious Diseases and Medical Microbiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- methicillin-resistant Staphylococcus aureus, MRSA bacteremia, recurrent bacteremia, linezolid, rifampicin, oral antibiotic therapy, vancomycin resistance, vancomycin intermediate resistance, metastatic infection, adverse drug reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.